Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1Infratentorial Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Vincristine 2Radiotherapy 2Cyclophosphamide 2Cisplatin 2Pemetrexed 1Maintenance Chemotherapy 1Lomustine 1Induction Chemotherapy 1HhAntag691 1Gemcitabine 1Exercise 1Diploidy 1Craniospinal Irradiation 1Carboplatin 1CLR1404 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroectodermal Tumors, Primitive × HhAntag691 × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡